MannKind partners with Rose Pharma on inhaled rapid-acting GLP-1 weight-loss therapy
MNKD•Development roles and consideration
MannKind will provide formulation, development, and manufacturing support through completion of a Phase 1b study in weight management.
Consideration includes an equity stake in Rose Pharma and potential royalties on future net sales; financial terms were not disclosed.
Rose Pharma will lead clinical development, regulatory strategy, and commercialization; MannKind will gain a board seat at Rose Pharma.
MannKind and Rose Pharma sign worldwide licensing and collaboration agreement
MannKind entered a worldwide licensing and collaboration agreement with Rose Pharma to develop ROSE-010 Technosphere for weight management.
Rose Pharma received exclusive rights to use MannKind’s Technosphere inhalation technology to develop and commercialize an inhaled rapid-acting GLP-1.
